Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Abstract

Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL) due to their reliable efficacy, manageable safety, high accessibility, and convenience for use. Still, no guidelines or consensus focusing on oral drug therapies for BCL is available. To provide a reference of oral agent-based treatment for mature BCL, a panel of experts from the Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association conducted an extensive discussion and reached a consensus on oral drugs for Chinese BCL patients on the basis of the current application status of oral drugs in China, combined with the latest authoritative guidelines in the world and current research reports. This consensus reviewed the application of oral drugs in the treatment of BCL and the latest research and provided appropriate recommendations on the use of oral drugs for indolent or aggressive BCL patients. With the deepening of research and the development of standardized clinical applications, oral medications will bring better treatment to BCL patients, enabling more patients to benefit from them.

Keywords

B-cell lymphoma / oral drug / targeted therapy / immunotherapy / COVID-19 pandemic

References

[1] GeneralOffice of the National Health Commission of the people’s Republic of China, Officeof the National Administration of Traditional Chinese Medicine. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). China Medicine 2020; 15( 6): 801– 805

[2] GuidelinesWorking Committee of Chinese Society of Clinical Oncology. Lymphoid Malignancies (2020 edition). Beijing: People’s Medical Publishing House, 2020

[3] NCCN Guidelines Insights: B-Cell Lymphomas, Version 2.2020. 2020. Available at NCCN website

[4] WierdaWG, ByrdJC, AbramsonJS, BilgramiSF, BociekG, BranderD, BrownJ, Chanan-KhanAA, ChavezJC, CoutreSE, DavisRS, FletcherCD, HillB, KahlBS, KamdarM, KaplanLD, KhanN, KippsTJ, LimMS, MaS, MalekS, MatoA, MosseC, ShadmanM, SiddiqiT, StephensD, SundaramS, WagnerN, DwyerM, SundarH. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18( 2): 185– 217

[5] NCCNClinical Practice Guidelines in Oncology. Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma. Version 1.2021. Fort Washington: National Comprehensive Cancer Network, 2021

[6] DreylingM, CampoE, HermineO, JerkemanM, LeGouill S, RuleS, ShpilbergO, WalewskiJ, LadettoM; ESMO Guidelines Committee. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28( suppl_4): iv62– iv71

[7] YoonDH, CaoJ, ChenTY, IzutsuK, KimSJ, KwongYL, LinTY, ThyeLS, XuB, YangDH, KimWS. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol 2020; 13( 1): 21

[8] HassettMJ, SomerfieldMR, BakerER, CardosoF, KansalKJ, KwaitDC, PlichtaJK, RickerC, RoshalA, RuddyKJ, SaferJD, Van PoznakC, YungRL, GiordanoSH. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020; 38( 16): 1849– 1863

[9] NeelapuSS, AdkinsS, AnsellSM, BrodyJ, CairoMS, FriedbergJW, KlineJP, LevyR, PorterDL, van BesienK, WernerM, BishopMR. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer 2020; 8( 2): e001235

[10] SwerdlowSH, CampoE, PileriSA, HarrisNL, SteinH, SiebertR, AdvaniR, GhielminiM, SallesGA, ZelenetzAD, JaffeES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127( 20): 2375– 2390

[11] ShanklandKR, ArmitageJO, HancockBW. Non-Hodgkin lymphoma. Lancet 2012; 380( 9844): 848– 857

[12] Pal SinghS, DammeijerF, HendriksRW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 2018; 17( 1): 57

[13] PonaderS, BurgerJA. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol 2014; 32( 17): 1830– 1839

[14] MccullochR RuleS EyreTA. Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 169 patients. Washington, DC: American Society of Hematology, 2019

[15] KarlinL BessonH TapprichC. Efficacy of ibrutinib-rituximab versus real-world (RW) treatments for patients with Waldenström’s macroglobulinemia (WM): adjusted comparison of iNNOVATE and the Lyon-Sud RW Database. Blood 2018; 132( Supplement 1): 1604

[16] SharmanJ KabadiS ClarkJ AmirianES AndorskyDJ. Treatment patterns and outcomes of 159 ibrutinib-treated MCL patients in the United States: a retrospective electronic medical record database and chart review study. Blood 2018; 132( Supplement 1): 4163 doi:10.1182/blood-2018–99-118848

[17] SallesG Callet-BauchuE BessonH. Single-agent ibrutinib vs real-world (RW) treatments for patients with chronic lymphocytic leukemia (CLL) and del11q: adjusted comparison of RESONATE-2TM and RESONATETM with RW Databases. Blood 2018; 132( Supplement 1): 4427

[18] GribbenJG, FowlerN, MorschhauserF. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 2015; 33( 25): 2803– 2811

[19] GillH, AuWY, CheungWW, LeeEY, KwongYL. Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma. Ann Oncol 2014; 25( 7): 1391– 1397

[20] NCCNClinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2021. Fort Washington: National Comprehensive Cancer Network, 2021

[21] BurgerJA, KeatingMJ, WierdaWG, HartmannE, HoellenriegelJ, RosinNY, deWeerdt I, JeyakumarG, FerrajoliA, Cardenas-TuranzasM, LernerS, JorgensenJL, Nogueras-GonzálezGM, ZacharianG, HuangX, KantarjianH, GargN, RosenwaldA, O’BrienS. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014; 15( 10): 1090– 1099

[22] ByrdJC, BrownJR, O’BrienS, BarrientosJC, KayNE, ReddyNM, CoutreS, TamCS, MulliganSP, JaegerU, DevereuxS, BarrPM, FurmanRR, KippsTJ, CymbalistaF, PocockC, ThorntonP, Caligaris-CappioF, RobakT, DelgadoJ, SchusterSJ, MontilloM, SchuhA, deVos S, GillD, BloorA, DeardenC, MorenoC, JonesJJ, ChuAD, FardisM, McGreivyJ, ClowF, JamesDF, HillmenP; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371( 3): 213– 223

[23] BurgerJA, TedeschiA, BarrPM, RobakT, OwenC, GhiaP, BaireyO, HillmenP, BartlettNL, LiJ, SimpsonD, GrosickiS, DevereuxS, McCarthyH, CoutreS, QuachH, GaidanoG, MaslyakZ, StevensDA, JanssensA, OffnerF, MayerJ, O’DwyerM, HellmannA, SchuhA, SiddiqiT, PolliackA, TamCS, SuriD, ChengM, ClowF, StylesL, JamesDF, KippsTJ; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373( 25): 2425– 2437

[24] DreylingM, JurczakW, JerkemanM, SilvaRS, RusconiC, TrnenyM, OffnerF, CaballeroD, JoaoC, Witzens-HarigM, HessG, Bence-BrucklerI, ChoSG, BothosJ, GoldbergJD, EnnyC, TrainaS, BalasubramanianS, BandyopadhyayN, SunS, VermeulenJ, RizoA, RuleS. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016; 387( 10020): 770– 778

[25] MunirT, BrownJR, O’BrienS, BarrientosJC, BarrPM, ReddyNM, CoutreS, TamCS, MulliganSP, JaegerU, KippsTJ, MorenoC, MontilloM, BurgerJA, ByrdJC, HillmenP, DaiS, SzokeA, DeanJP, WoyachJA. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019; 94( 12): 1353– 1363

[26] BurgerJA, BarrPM, RobakT, OwenC, GhiaP, TedeschiA, BaireyO, HillmenP, CoutreSE, DevereuxS, GrosickiS, McCarthyH, SimpsonD, OffnerF, MorenoC, DaiS, LalI, DeanJP, KippsTJ. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020; 34( 3): 787– 798

[27] ByrdJC, FurmanRR, CoutreSE, FlinnIW, BurgerJA, BlumK, SharmanJP, WierdaW, ZhaoW, HeeremaNA, LuanY, LiuEA, DeanJP, O’BrienS. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res 2020; 26( 15): 3918– 3927

[28] XuW, YangS, ZhouK, PanL, LiZ, ZhouJ, GaoS, ZhouD, HuJ, FengR, HuangH, JiM, GuoH, HuangJ, NovotnyW, FengS, LiJ. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol 2020; 13( 1): 48

[29] StratiP, TakahashiK, PetersonCB, KeatingMJ, ThompsonPA, DaverNG, JainN, BurgerJA, EstrovZ, O’BrienSM, KantarjianHM, WierdaWG, FutrealPA, FerrajoliA. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 2019; 3( 9): 1533– 1539

[30] HematologyOncology Committee of China Anti-Cancer Association Leukemia & Lymphoma Group Society of Hematology at Chinese Medical Association Unionfor China Lymphoma Investigators. The consensus of the diagnosis and treatment of lymphoplasmacytic lymphoma/Walderström macroglobulinemia in China (2016 version). Chin J Hematol (Zhonghua Xue Ye Xue Za Zhi) 2016; 37(9): 729– 734 (in Chinese)

[31] TreonSP, TripsasCK, MeidK, WarrenD, VarmaG, GreenR, ArgyropoulosKV, YangG, CaoY, XuL, PattersonCJ, RodigS, ZehnderJL, AsterJC, HarrisNL, KananS, GhobrialI, CastilloJJ, LaubachJP, HunterZR, SalmanZ, LiJ, ChengM, ClowF, GraefT, PalombaML, AdvaniRH. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015; 372( 15): 1430– 1440

[32] DimopoulosMA, TrotmanJ, TedeschiA, MatousJV, MacdonaldD, TamC, TournilhacO, MaS, OriolA, HeffnerLT, ShustikC, García-SanzR, CornellRF, deLarrea CF, CastilloJJ, GranellM, KyrtsonisMC, LeblondV, SymeonidisA, KastritisE, SinghP, LiJ, GraefT, BilottiE, TreonS, BuskeC; the iNNOVATE Study Group, theEuropean Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017; 18( 2): 241– 250

[33] TamCS OpatS D’SaS JurczakW LeeHP CullG OwenRG MarltonP WahlinBE SanzRG McCarthyH MulliganS TedeschiA CastilloJJ CzyzJ Fernandezde Larrea C BeladaD LibbyE MatousJV MottaM SiddiqiT TaniM TrnenyM MinnemaMC BuskeC LeblondV TrotmanJ ChanWY SchneiderJ RoS Cohen A HuangJ DimopoulosM. ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM). J Clin Oncol 2020; 38( 15 suppl): 8007 doi:10.1200/JCO.2020.38.15_suppl.8007

[34] TamCS, OpatS, D’SaS, JurczakW, LeeHP, CullG, OwenRG, MarltonP, WahlinBE, SanzRG, McCarthyH, MulliganS, TedeschiA, CastilloJJ, CzyzJ, Fernándezde Larrea C, BeladaD, LibbyE, MatousJV, MottaM, SiddiqiT, TaniM, TrnenyM, MinnemaMC, BuskeC, LeblondV, TrotmanJ, ChanWY, SchneiderJ, RoS, CohenA, HuangJ, DimopoulosM. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020; 136( 18): 2038– 2050

[35] NastoupilL LeeH Hagemeister F WestinJR SamaniegoF FengL JohnJ ForbesSG FayadLE GreenMR DavisRE NeelapuSS FowlerNH. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: an open label, phase II study. Blood 2018; 132(Supplement 1): 447 doi:10.1182/blood- 2018– 99-113721

[36] KiesewetterB, WillenbacherE, WillenbacherW, EgleA, NeumeisterP, VoskovaD, MayerhoeferME, Simonitsch-KluppI, MelchardtT, GreilR, RadererM; AGMT Investigators. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood 2017; 129( 3): 383– 385

[37] NoyA, de VosS, ThieblemontC, MartinP, FlowersCR, MorschhauserF, CollinsGP, MaS, ColemanM, PelesS, SmithS, BarrientosJC, SmithA, MunnekeB, DimeryI, BeaupreDM, ChenR. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129( 16): 2224– 2232

[38] MartinP, JungSH, PitcherB, BartlettNL, BlumKA, SheaT, HsiED, RuanJ, SmithSE, LeonardJP, ChesonBD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 2017; 28( 11): 2806– 2812

[39] MorschhauserF, FowlerNH, FeugierP, BouabdallahR, TillyH, PalombaML, FruchartC, LibbyEN, CasasnovasRO, FlinnIW, HaiounC, MaisonneuveH, YsebaertL, BartlettNL, BouabdallahK, BriceP, RibragV, DaguindauN, LeGouill S, PicaGM, MartinGarcia-Sancho A, López-GuillermoA, LaroucheJF, AndoK, Gomesda Silva M, AndréM, ZachéeP, SehnLH, TobinaiK, CartronG, LiuD, WangJ, XerriL, SallesGA; RELEVANCE Trial Investigators. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018; 379( 10): 934– 947

[40] RuanJ, MartinP, ShahB, SchusterSJ, SmithSM, FurmanRR, ChristosP, RodriguezA, SvobodaJ, LewisJ, KatzO, ColemanM, LeonardJP. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med 2015; 373( 19): 1835– 1844

[41] WangML, RuleS, MartinP, GoyA, AuerR, KahlBS, JurczakW, AdvaniRH, RomagueraJE, WilliamsME, BarrientosJC, ChmielowskaE, RadfordJ, StilgenbauerS, DreylingM, JedrzejczakWW, JohnsonP, SpurgeonSE, LiL, ZhangL, NewberryK, OuZ, ChengN, FangB, McGreivyJ, ClowF, BuggyJJ, ChangBY, BeaupreDM, KunkelLA, BlumKA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369( 6): 507– 516

[42] RuleS, DreylingM, GoyA, HessG, AuerR, KahlB, Hernández-RivasJA, QiK, DeshpandeS, ParisiL, WangM. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica 2019; 104( 5): e211– e214

[43] SongY, ZhouK, ZouD, ZhouJ, HuJ, YangH, ZhangH, JiJ, XuW, JinJ, LvF, FengR, GaoS, GuoH, ZhouL, ElstromR, HuangJ, NovotnyW, WeiR, ZhuJ. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine kinase. Clin Cancer Res 2020; 26( 16): 4216– 4224

[44] YounesA, SehnLH, JohnsonP, ZinzaniPL, HongX, ZhuJ, PattiC, BeladaD, SamoilovaO, SuhC, LeppäS, RaiS, TurgutM, JurczakW, CheungMC, GurionR, YehSP, Lopez-HernandezA, DührsenU, ThieblemontC, ChiattoneCS, BalasubramanianS, CareyJ, LiuG, ShreeveSM, SunS, ZhuangSH, VermeulenJ, StaudtLM, WilsonW; PHOENIX investigators. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019; 37( 15): 1285– 1295

[45] ZhuJ Hong X SongY. Ibrutinib + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) in patients with untreated non-germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL): a Chinese subgroup analysis of the phase 3 PHOENIX trial. Journal of Clinical Oncology, Abstracts of the 23rd Annual Meeting of Chinese Society of Clinical Oncology 2020. 50

[46] WilsonWH, YoungRM, SchmitzR, YangY, PittalugaS, WrightG, LihCJ, WilliamsPM, ShafferAL, GerecitanoJ, de VosS, GoyA, KenkreVP, BarrPM, BlumKA, ShustovA, AdvaniR, FowlerNH, VoseJM, ElstromRL, HabermannTM, BarrientosJC, McGreivyJ, FardisM, ChangBY, ClowF, MunnekeB, MoussaD, BeaupreDM, StaudtLM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21( 8): 922– 926

[47] WangM, FowlerN, Wagner-BartakN, FengL, RomagueraJ, NeelapuSS, HagemeisterF, FanaleM, OkiY, ProB, ShahJ, ThomasS, YounesA, HosingC, ZhangL, NewberryKJ, DesaiM, ChengN, BadilloM, BejaranoM, ChenY, YoungKH, ChamplinR, KwakL, FayadL. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27( 9): 1902– 1909

[48] ZhangMC, FangY, WangL, ChengS, FuD, HeY, ZhaoY, WangCF, JiangXF, SongQ, XuPP, ZhaoWL. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Clin Epigenetics 2020; 12( 1): 160

[49] LionakisMS, DunleavyK, RoschewskiM, WidemannBC, ButmanJA, SchmitzR, YangY, ColeDE, MelaniC, HighamCS, DesaiJV, CeribelliM, ChenL, ThomasCJ, LittleRF, Gea-BanaclocheJ, BhaumikS, Stetler-StevensonM, PittalugaS, JaffeES, HeissJ, LucasN, SteinbergSM, StaudtLM, WilsonWH. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 2017; 31( 6): 833– 843.e5

[50] GoldwirtL, BeccariaK, PleA, SauvageonH, MourahS. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol 2018; 81( 4): 783– 789

[51] GrommesC, PastoreA, PalaskasN, TangSS, CamposC, SchartzD, CodegaP, NicholD, ClarkO, HsiehWY, RohleD, RosenblumM, VialeA, TabarVS, BrennanCW, GavrilovicIT, KaleyTJ, NolanCP, OmuroA, PentsovaE, ThomasAA, TsyvkinE, NoyA, PalombaML, HamlinP, SauterCS, MoskowitzCH, WolfeJ, DoganA, WonM, GlassJ, PeakS, LallanaEC, HatzoglouV, ReinerAS, GutinPH, HuseJT, PanageasKS, GraeberTG, SchultzN, DeAngelisLM, MellinghoffIK. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 2017; 7( 9): 1018– 1029

[52] MehtaV, GoelS, KabarritiR, ColeD, GoldfingerM, Acuna-VillaordunaA, PradhanK, ThotaR, ReissmanS, SparanoJA, GartrellBA, SmithRV, OhriN, GargM, RacineAD, KalnickiS, Perez-SolerR, HalmosB, VermaA. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov 2020; 10( 7): 935– 941

[53] PassamontiF, CattaneoC, ArcainiL, BrunaR, CavoM, MerliF, AngelucciE, KramperaM, CairoliR, DellaPorta MG, FracchiollaN, LadettoM, GambacortiPasserini C, SalviniM, MarchettiM, LemoliR, MolteniA, BuscaA, CuneoA, RomanoA, GiulianiN, GalimbertiS, CorsoA, MorottiA, FaliniB, BillioA, GherlinzoniF, VisaniG, TisiMC, TafuriA, TosiP, LanzaF, MassaiaM, TurriniM, FerraraF, GurrieriC, VallisaD, MartelliM, DerenziniE, GuariniA, ConconiA, CuccaroA, CudilloL, RussoD, CiambelliF, ScattolinAM, LuppiM, SelleriC, OrtuLa Barbera E, FerrandinaC, DiRenzo N, OlivieriA, BocchiaM, GentileM, MarchesiF, MustoP, FedericiAB, CandoniA, VendittiA, FavaC, PintoA, GalieniP, RigacciL, ArmientoD, PaneF, ObertiM, ZappasodiP, ViscoC, FranchiM, GrossiPA, BertùL, CorraoG, PaganoL, CorradiniP; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020; 7( 10): e737– e745

[54] XiaoY CaoY Huang L ZhengM ZhouJF. Management of patients with hematological malignancies in outbreak areas of COVID-19 epidemic: our experience at Wuhan Tongji Hospital. Chin J Hematol (Zhonghua Xue Ye Xue Za Zhi) 2020; 41(7): 612– 614 (in Chinese)

[55] RoschewskiM, LionakisMS, SharmanJP, RoswarskiJ, GoyA, MonticelliMA, RoshonM, WrzesinskiSH, DesaiJV, ZarakasMA, CollenJ, RoseK, HamdyA, IzumiR, WrightGW, ChungKK, BaselgaJ, StaudtLM, WilsonWH. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol 2020; 5( 48): eabd0110

[56] TreonSP, CastilloJJ, SkarbnikAP, SoumeraiJD, GhobrialIM, GuerreraML, MeidK, YangG. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135( 21): 1912– 1915

[57] ChongEA, RoekerLE, ShadmanM, DavidsMS, SchusterSJ, MatoAR. BTK inhibitors in cancer patients with COVID-19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020; 26( 14): 3514– 3516

[58] MatoAR, RoekerLE, LamannaN, AllanJN, LeslieL, PagelJM, PatelK, OsterborgA, WojenskiD, KamdarM, HuntingtonSF, DavidsMS, BrownJR, AnticD, JacobsR, AhnIE, PuJ, IsaacKM, BarrPM, UjjaniCS, GeyerMB, BermanE, ZelenetzAD, MalakhovN, FurmanRR, KoropsakM, BaileyN, HansonL, PeriniGF, MaS, RyanCE, WiestnerA, PortellCA, ShadmanM, ChongEA, BranderDM, SundaramS, SeddonAN, SeymourE, PatelM, Martinez-CalleN, MunirT, WalewskaR, BroomA, WalterH, El-SharkawiD, ParryH, WilsonMR, PattenPEM, Hernández-RivasJÁ, MirasF, FernándezEscalada N, GhioneP, NabhanC, LebowitzS, BhavsarE, López-JiménezJ, NayaD, Garcia-MarcoJA, SkånlandSS, CordobaR, EyreTA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020; 136( 10): 1134– 1143

[59] ChineseSociety of Clinical Oncology (CSCO) Anti-Leukemia Alliance Chinese Society of Clinical Oncology (CSCO) Anti-Lymphoma Alliance. Chinese expert consensus on the ibrutinib treatment in B-cell malignancies (2019 version). J Leuk Lymphoma (Bai Xue Bing·Lin Ba Liu) 2019; 28( 8): 449– 456 (in Chinese)

[60] CoutreSE, ByrdJC, HillmenP, BarrientosJC, BarrPM, DevereuxS, RobakT, KippsTJ, SchuhA, MorenoC, FurmanRR, BurgerJA, O’DwyerM, GhiaP, ValentinoR, ChangS, DeanJP, JamesDF, O’BrienSM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 2019; 3( 12): 1799– 1807

[61] FowlerNH, DavisRE, RawalS, NastoupilL, HagemeisterFB, McLaughlinP, KwakLW, RomagueraJE, FanaleMA, FayadLE, WestinJR, ShahJ, OrlowskiRZ, WangM, TurturroF, OkiY, ClaretLC, FengL, BaladandayuthapaniV, MuzzafarT, TsaiKY, SamaniegoF, NeelapuSS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15( 12): 1311– 1318

[62] GarciazS, CosoD, Schiano de ColellaJM, BouabdallahR. Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs 2016; 25( 9): 1103– 1116

RIGHTS & PERMISSIONS

Higher Education Press